Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation

Deborah L. Marrocco, Wayne D. Tilley, Tina Bianco-Miotto, Andreas Evdokiou, Howard I. Scher, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon and Lisa M. Butler
Deborah L. Marrocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne D. Tilley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina Bianco-Miotto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Evdokiou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard I. Scher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Rifkind
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul A. Marks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria M. Richon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa M. Butler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-06-0144 Published January 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: January 2007 to January 2021

AbstractFull-text HTMLPDF
Total311134492377

Cited By

Article Information

Volume 6, Issue 1, pp. 51-60

DOI 
https://doi.org/10.1158/1535-7163.MCT-06-0144
PubMed 
17218635

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • November 16, 2006
  • March 17, 2006
  • October 6, 2006
  • Published first January 11, 2007.

Article Versions

  • Previous version (January 11, 2007 - 13:49).
  • You are viewing the most recent version of this article.
Copyright & Usage 
American Association for Cancer Research

Author Information

  1. Deborah L. Marrocco1,
  2. Wayne D. Tilley1,
  3. Tina Bianco-Miotto1,
  4. Andreas Evdokiou2,
  5. Howard I. Scher3,
  6. Richard A. Rifkind4,
  7. Paul A. Marks4,
  8. Victoria M. Richon5 and
  9. Lisa M. Butler1
  1. 1Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide, Hanson Institute, Adelaide, South Australia, Australia; 2Department of Orthopaedics and Trauma, Royal Adelaide Hospital, Adelaide, South Australia, Australia; 3Genitourinary Oncology Service, and 4Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 5Merck & Co., Inc., Boston, Massachusetts
  1. Requests for reprints: Lisa M. Butler, Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide, Hanson Institute, Adelaide, South Australia 5000, Australia. Phone: 618-8222-3270; Fax: 618-8222-3217. E-mail: lisa.butler{at}imvs.sa.gov.au
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 6 (1)
January 2007
Volume 6, Issue 1
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Deborah L. Marrocco, Wayne D. Tilley, Tina Bianco-Miotto, Andreas Evdokiou, Howard I. Scher, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon and Lisa M. Butler
Mol Cancer Ther January 1 2007 (6) (1) 51-60; DOI: 10.1158/1535-7163.MCT-06-0144

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Deborah L. Marrocco, Wayne D. Tilley, Tina Bianco-Miotto, Andreas Evdokiou, Howard I. Scher, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon and Lisa M. Butler
Mol Cancer Ther January 1 2007 (6) (1) 51-60; DOI: 10.1158/1535-7163.MCT-06-0144
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
  • Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement